Adial Pharmaceuticals, Inc. (ADIL)
5.95
-0.70
(-10.53%)
USD |
NASDAQ |
Sep 09, 10:55
Adial Pharmaceuticals Enterprise Value : 51.10M for Sept. 8, 2026
Enterprise Value Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Enterprise Value Data
| Date | Value |
|---|---|
| September 08, 2026 | 51.10M |
| September 04, 2026 | 52.33M |
| September 03, 2026 | 51.12M |
| September 02, 2026 | 50.23M |
| September 01, 2026 | 49.26M |
| August 31, 2026 | 48.73M |
| August 28, 2026 | 48.34M |
| August 27, 2026 | 48.57M |
| August 26, 2026 | 49.23M |
| August 25, 2026 | 48.92M |
| August 24, 2026 | 47.81M |
| August 21, 2026 | 49.95M |
| August 20, 2026 | 49.13M |
| August 19, 2026 | 48.75M |
| August 18, 2026 | 47.94M |
| August 17, 2026 | 46.74M |
| August 14, 2026 | 44.08M |
| August 13, 2026 | 45.16M |
| August 12, 2026 | 44.95M |
| August 11, 2026 | 44.95M |
| August 10, 2026 | 44.69M |
| August 07, 2026 | 44.08M |
| August 06, 2026 | 46.24M |
| August 05, 2026 | 44.27M |
| August 04, 2026 | 43.61M |
| Date | Value |
|---|---|
| August 03, 2026 | 43.19M |
| July 31, 2026 | 42.40M |
| July 30, 2026 | 42.27M |
| July 29, 2026 | 41.90M |
| July 28, 2026 | 41.38M |
| July 27, 2026 | 41.01M |
| July 24, 2026 | 40.93M |
| July 23, 2026 | 40.67M |
| July 22, 2026 | 40.72M |
| July 21, 2026 | 40.83M |
| July 20, 2026 | 40.80M |
| July 17, 2026 | 40.99M |
| July 16, 2026 | 40.96M |
| July 15, 2026 | 40.78M |
| July 14, 2026 | 40.59M |
| July 13, 2026 | 41.06M |
| July 10, 2026 | 40.93M |
| July 09, 2026 | 40.99M |
| July 08, 2026 | 41.17M |
| July 07, 2026 | 41.27M |
| July 06, 2026 | 41.25M |
| July 02, 2026 | 41.25M |
| July 01, 2026 | 41.01M |
| June 30, 2026 | 40.36M |
| June 29, 2026 | -0.6753M |
Enterprise Value Definition
EV is considered the theoretical purchase ("takeover") price of a business because a purchaser would take on the company's debt, while pocketing the company's cash and gaining a right to all of the company's future earnings.
Enterprise Value Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Enterprise Value Benchmarks
| Eli Lilly & Co. | 1.104T |
| ANI Pharmaceuticals, Inc. | 1.848B |
| Corcept Therapeutics, Inc. | 12.00B |
| Veru, Inc. | 20.88M |
| Johnson & Johnson | 676.38B |
Enterprise Value Related Metrics
| Net Income (Quarterly) | -51.99M |
| Total Expenses (Quarterly) | 51.99M |
| EPS Diluted (Quarterly) | -11.25 |
| Earnings Yield | -278.1% |
| Normalized Earnings Yield | -166.15 |